RTOG®
RADIATION THERAPY ONCOLOGY GROUP

Scientific & Plenary Sessions

Saturday, January 21, 2012
RTOG Semiannual Meeting
Atlanta, GA

1:00 PM Scientific Session

INTRODUCTION

Maria Werner-Wasik, MD, RTOG Vice-Chair of Publications, Thomas Jefferson University Hospital

SCIENTIFIC PRESENTATIONS

Jeffrey Michalski, MD,Washington Univeristy

Preliminary Analysis of RTOG 0126 High Dose Arm Prostate Patients Receiving 3DCRT or IMRT: Toxicity Report

Michalski JM, Yan Y, Bruner DW, Bosch W, Winter K, Galvin JM, Bahary JP, Morton GC, Parliament MB, Sandler H

Deborah Watkins Bruner, RN, PhD, FAAN, Emory University

Preliminary Analysis of RTOG 0126 High Dose Arm Prostate Patients Receiving 3DCRT or IMRT: Patient Reported Outcomes

Bruner DW, Hunt D, Michalski JM, Bosch W, Yan Y, Galvin JM, Bahary JP, Morton GC, Parliament MB, Sandler H

Q&A / Discussion

Mitchell Machtay, MD, Case Western Reserve Univeristy

Can FDG-PET Standardized Uptake Value (SUV) findings predict Local Control in Stage III NSCLC?: Preliminary Results from ACRIN 6668/RTOG 0235

Machtay M, Duan F, Snyder B, Gorelick J, DeNittis A, Chiles C, Mahon I, Alavi A, Siegel B, Bradley J

Jeffrey Bradley, MD, Washington Univeristy

A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus High-dose (74 Gy) Conformal Chemoradiotherapy +/- Cetuximab for Stage IIIA/IIIB Non-Small Cell Lung Cancer: Preliminary Findings on Radiation Dose in RTOG 0617

Bradley JD, Paulus R, Komaki R, Masters G, Forster K, Schild S, Bogart JA, Garces YI, Narayan S, Choy H

Q&A / Discussion

2:00 PM Plenary Session

KEYNOTE ADDRESS

GOG Organizational Structure and Accomplishments

Philip J. DiSaia, MD, GOG Group Chair, University of California - Irvine

RTOG GROUP CHAIR UPDATE

Walter J. Curran, Jr., MD, RTOG Group Chair, Winship Cancer Institute of Emory University